IDR 1002 | CAS# 1224095-25-3 | Peptide

MedKoo Cat#: 112204 | Name: IDR-1002 TFA

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

IDR 1002 is a synthetic cationic innate defense regulator peptide that increases the numbers of neutrophils and monocytes in mouse peritoneum and protects against S. aureus and E. coli infections in mice.

Chemical Structure

IDR-1002 TFA

CAS#1224095-25-3 (free base)

Theoretical Analysis

MedKoo Cat#: 112204

Name: IDR-1002 TFA

CAS#: 1224095-25-3 (free base)

Chemical Formula: C82H134F2N26O15

Exact Mass: 1651.0311

Molecular Weight: 1762.14

Elemental Analysis: C, 55.89; H, 7.67; F, 2.16; N, 20.67; O, 13.62

Price and Availability

Size	Price	Availability
5mg	USD 450.00	2 Weeks
10mg	USD 750.00	2 Weeks
25mg	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1224095-25-3 (free base)

Synonym

IDR 1002; IDR-1002; IDR1002;

IUPAC/Chemical Name

(S)-2-((S)-2-amino-3-methylbutanamido)-N1-((6S,9S,12S,15S,18S,21S,24S,27S,30S,33S)-9,21-bis((1H-indol-3-yl)methyl)-1,37-diamino-15,27-di((S)-sec-butyl)-33-carbamoyl-24,30-bis(3-guanidinopropyl)-1-imino-12-isobutyl-18-isopropyl-7,10,13,16,19,22,25,28,31-nonaoxo-2,8,11,14,17,20,23,26,29,32-decaazaheptatriacontan-6-yl)pentanediamide trifluoroacetic acid

InChi Key

UZQFRGFLFPQJGO-NEORNSIFSA-N

InChi Code

InChI=1S/C79H130N26O13.C3H4F2O2/c1-11-44(9)63(75(117)99-54(28-20-34-91-78(86)87)66(108)95-52(65(83)107)26-17-18-32-80)104-69(111)55(29-21-35-92-79(88)89)97-70(112)59(38-47-40-94-51-25-16-14-23-49(47)51)102-74(116)62(43(7)8)103-76(118)64(45(10)12-2)105-72(114)57(36-41(3)4)100-71(113)58(37-46-39-93-50-24-15-13-22-48(46)50)101-67(109)53(27-19-33-90-77(84)85)96-68(110)56(30-31-60(81)106)98-73(115)61(82)42(5)6;1-3(4,5)2(6)7/h13-16,22-25,39-45,52-59,61-64,93-94H,11-12,17-21,26-38,80,82H2,1-10H3,(H2,81,106)(H2,83,107)(H,95,108)(H,96,110)(H,97,112)(H,98,115)(H,99,117)(H,100,113)(H,101,109)(H,102,116)(H,103,118)(H,104,111)(H,105,114)(H4,84,85,90)(H4,86,87,91)(H4,88,89,92);1H3,(H,6,7)/t44-,45-,52-,53-,54-,55-,56-,57-,58-,59-,61-,62-,63-,64-;/m0./s1

SMILES Code

NCCCC[C@@H](C(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCC(N)=O)NC([C@@H](N)C(C)C)=O)=O)=O)CC1=CNC2=CC=CC=C12)=O)=O)=O)=O)CC3=CNC4=CC=CC=C34)=O)=O)=O)=O.OC(C(C)(F)F)=O

Appearance

To be determined

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,762.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sousa MGC, Xavier PD, Cantuária APC, Porcino RA, Almeida JA, Franco OL, Rezende TMB. Host defense peptide IDR-1002 associated with ciprofloxacin as a new antimicrobial and immunomodulatory strategy for dental pulp revascularization therapy. Microb Pathog. 2021 Mar;152:104634. doi: 10.1016/j.micpath.2020.104634. Epub 2020 Nov 23. PMID: 33242643. 2: Wuerth KC, Falsafi R, Hancock REW. Synthetic host defense peptide IDR-1002 reduces inflammation in Pseudomonas aeruginosa lung infection. PLoS One. 2017 Nov 6;12(11):e0187565. doi: 10.1371/journal.pone.0187565. PMID: 29107983; PMCID: PMC5673212. 3: Huante-Mendoza A, Silva-García O, Oviedo-Boyso J, Hancock RE, Baizabal- Aguirre VM. Peptide IDR-1002 Inhibits NF-κB Nuclear Translocation by Inhibition of IκBα Degradation and Activates p38/ERK1/2-MSK1-Dependent CREB Phosphorylation in Macrophages Stimulated with Lipopolysaccharide. Front Immunol. 2016 Nov 25;7:533. doi: 10.3389/fimmu.2016.00533. PMID: 27933067; PMCID: PMC5122595. 4: Niyonsaba F, Madera L, Afacan N, Okumura K, Ogawa H, Hancock RE. The innate defense regulator peptides IDR-HH2, IDR-1002, and IDR-1018 modulate human neutrophil functions. J Leukoc Biol. 2013 Jul;94(1):159-70. doi: 10.1189/jlb.1012497. Epub 2013 Apr 24. PMID: 23616580. 5: Piyadasa H, Hemshekhar M, Osawa N, Lloyd D, Altieri A, Basu S, Krokhin OV, Halayko AJ, Mookherjee N. Disrupting Tryptophan in the Central Hydrophobic Region Selectively Mitigates Immunomodulatory Activities of the Innate Defence Regulator Peptide IDR-1002. J Med Chem. 2021 May 27;64(10):6696-6705. doi: 10.1021/acs.jmedchem.0c02065. Epub 2021 May 11. PMID: 33974425. 6: Madera L, Hancock RE. Synthetic immunomodulatory peptide IDR-1002 enhances monocyte migration and adhesion on fibronectin. J Innate Immun. 2012;4(5-6):553-68. doi: 10.1159/000338648. Epub 2012 Jun 19. PMID: 22722749; PMCID: PMC6741481. 7: Rivas-Santiago B, Castañeda-Delgado JE, Rivas Santiago CE, Waldbrook M, González-Curiel I, León-Contreras JC, Enciso-Moreno JA, del Villar V, Mendez- Ramos J, Hancock RE, Hernandez-Pando R. Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models. PLoS One. 2013;8(3):e59119. doi: 10.1371/journal.pone.0059119. Epub 2013 Mar 21. PMID: 23555622; PMCID: PMC3605426. 8: Madera L, Hancock RE. Anti-infective peptide IDR-1002 augments monocyte chemotaxis towards CCR5 chemokines. Biochem Biophys Res Commun. 2015 Aug 28;464(3):800-6. doi: 10.1016/j.bbrc.2015.07.038. Epub 2015 Jul 10. PMID: 26168734. 9: Levast B, Hogan D, van Kessel J, Strom S, Walker S, Zhu J, Meurens F, Gerdts V. Synthetic Cationic Peptide IDR-1002 and Human Cathelicidin LL37 Modulate the Cell Innate Response but Differentially Impact PRRSV Replication in vitro. Front Vet Sci. 2019 Jul 12;6:233. doi: 10.3389/fvets.2019.00233. PMID: 31355218; PMCID: PMC6640542. 10: Wuerth K, Lee AHY, Falsafi R, Gill EE, Hancock REW. Characterization of Host Responses during Pseudomonas aeruginosa Acute Infection in the Lungs and Blood and after Treatment with the Synthetic Immunomodulatory Peptide IDR-1002. Infect Immun. 2018 Dec 19;87(1):e00661-18. doi: 10.1128/IAI.00661-18. PMID: 30323028; PMCID: PMC6300642. 11: Nijnik A, Madera L, Ma S, Waldbrook M, Elliott MR, Easton DM, Mayer ML, Mullaly SC, Kindrachuk J, Jenssen H, Hancock RE. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J Immunol. 2010 Mar 1;184(5):2539-50. doi: 10.4049/jimmunol.0901813. Epub 2010 Jan 27. PMID: 20107187. 12: Turner-Brannen E, Choi KY, Lippert DN, Cortens JP, Hancock RE, El-Gabalawy H, Mookherjee N. Modulation of interleukin-1β-induced inflammatory responses by a synthetic cationic innate defence regulator peptide, IDR-1002, in synovial fibroblasts. Arthritis Res Ther. 2011 Aug 11;13(4):R129. doi: 10.1186/ar3440. PMID: 21835002; PMCID: PMC3239371.